SEC Tracker
Get the app
MBRX · XBRL financial data

Moleculin Biotech financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (MBRX's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue00*0000*0000*00
Research and development3,2806,632*4,2524,0904,9324,455*3,4353,6003,7385,117*5,3785,450
General and administrative2,6352,252*2,3932,0642,1722,157*2,4772,0912,1472,407*2,4882,103
Total operating expenses5,9478,919*6,6776,1857,1356,643*5,9435,7205,9067,533*7,8747,561
Operating income (loss)(5,947)(8,919)*(6,677)(6,185)(7,135)(6,643)*(5,943)(5,720)(5,906)(7,533)*(7,874)(7,561)
Other income (expense)1318*1111912*9416(50)*7613
Income tax expense (benefit)00*0000*0000*00
Net income (loss)(5,609)(10,269)*(4,970)(4,319)(10,592)(1,882)*(6,436)(7,640)(25,399)15,552*(12,845)(7,635)
Earnings per share, basic USD per share(0.19)—(2.02)(1.70)(2.85)—(0.69)(0.49)(0.68)—(3.54)(1.40)
Weighted average shares, basic thousands of shares29,809—2,4662,5433,714—9,34415,52637,304—4,1245,681
  • † Share count changed about 1/13 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (MBRX's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents24,57923,55016,82410,8459,4054,2787,7167,5576,7038,87810,3177,262
Prepaid and other current assets3,0242,7232,1332,8862,2019161,6241,5191,1828086441,461
Total current assets27,60326,27318,95713,73111,6065,1949,3409,0767,8859,68610,9618,723
Property and equipment, net2252722402211901591279977787062
Right-of-use asset547524500475450424398370343314284254
Total assets39,52338,21730,84525,57523,39416,92521,01321,59320,35322,12623,36321,087
Accounts payable2,0082,4982,1042,8332,5502,0302,7063,7212,1163,5084,5744,337
Accrued liabilities1,8804,3173,3042,9133,0433,3294,1904,1923,5663,3463,3884,976
Total current liabilities3,8886,8155,4085,7465,5935,3596,8967,9135,6826,8547,9629,313
Lease liability, non-current496474450420390358326292258222185147
Total liabilities4,38512,1449,2587,87015,91510,94620,97128,75847,2737,1208,1809,500
Accumulated deficit(121,335)(131,604)(136,574)(140,893)(151,485)(153,367)(159,803)(167,443)(221,556)(206,004)(218,849)(226,484)
Total stockholders' equity35,13826,07321,58717,7057,4795,97942(7,165)(26,920)15,00615,18311,587
Total liabilities and equity39,52338,21730,84525,57523,39416,92521,01321,59320,35322,12623,36321,087
Common shares outstanding (cover page) thousands of shares29,8102,2282,3122,5623,00214,00014,12730,28650,9105,3365,33619,477
  • † Share count changed about 1/13 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (MBRX's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(5,609)(10,269)*(4,970)(4,319)(10,592)(1,882)*(6,436)(7,640)(25,399)15,552*(12,845)(7,635)
Stock-based compensation493*479*493453*353*427*485417*303*459*380436*
Depreciation and amortization3235*32313131*3129219*88
Net cash from operating activities(7,551)*(5,407)*(6,717)(5,949)*(6,113)*(5,083)*(4,564)(5,582)*(7,223)*(5,366)*(6,111)(6,657)*
Purchases of property and equipment28*81*013*0*0*00*0*0*——
Net cash from investing activities(28)*(81)*0(13)*0*0*00*0*0*00*
Proceeds from issuing common stock0*—00*————————
Net cash from financing activities(4)*4,465*0(25)*4,659*1*7,9995,423*6,375*7,487*7,6123,613*
Net change in cash(7,593)*(1,029)*(6,726)(5,979)*(1,440)*(5,127)*3,438(159)*(854)*2,175*1,439(3,055)*
  • † Share count changed about 1/13 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Moleculin Biotech7,2620(6,657)*19.5M1.1 quarters 10-QJun 30, 2026
GT Biopharma4,960not reported(4,260)*45.1M1.2 quarters 10-QJun 30, 2026
TherapeuticsMD9,189not reportednot reported11.6M— 10-QJun 30, 2026
Oncotelic Therapeutics186250(92)*457.5M2.0 quarters 10-QJun 30, 2026
Biovie8,977not reported(4,122)*7.5M2.2 quarters 10-KJun 30, 2026
Artelo Biosciences4,198not reported(5,033)*4.6M0.8 quarters 10-QJun 30, 2026
Bioxytran177not reported(350)*114.7M0.5 quarters 10-QJun 30, 2026
Talphera742not reported(3,924)*51.9M4.4 quarters 10-QJun 30, 2026
Raphael Pharmaceutical1not reported0*20.2M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.